Maze Therapeutics (NASDAQ:MAZE) Issues Earnings Results

Maze Therapeutics (NASDAQ:MAZE) issued its quarterly earnings results on Thursday. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.08, Zacks reports.

Maze Therapeutics Trading Down 3.5%

Shares of NASDAQ MAZE traded down $1.03 during mid-day trading on Friday, reaching $28.60. 331,877 shares of the company’s stock were exchanged, compared to its average volume of 321,356. Maze Therapeutics has a twelve month low of $6.71 and a twelve month high of $34.29. The firm has a market capitalization of $1.25 billion and a price-to-earnings ratio of -1.37. The business has a fifty day simple moving average of $25.85 and a 200 day simple moving average of $17.21.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc boosted its stake in Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after purchasing an additional 3,371 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Maze Therapeutics by 452.5% during the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock worth $57,000 after buying an additional 3,774 shares during the period. Bank of America Corp DE grew its holdings in shares of Maze Therapeutics by 33.6% during the second quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock worth $71,000 after buying an additional 1,455 shares in the last quarter. Engineers Gate Manager LP bought a new position in shares of Maze Therapeutics during the second quarter worth about $125,000. Finally, Vanguard Group Inc. raised its position in Maze Therapeutics by 218.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after buying an additional 915,342 shares during the last quarter.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Guggenheim boosted their target price on Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday, September 15th. Wedbush upped their price target on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research note on Friday. Finally, BTIG Research lifted their price objective on shares of Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $37.00.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.